Treatment Paradigms. Shifted.
The ELIAS cancer immunotherapy (ECI
®) platform offers a completely new approach to cancer treatment. It is built upon 50+ years of intensive
scientific and medical research into the interactions between cancer and the immune response. ECI utilizes a
combination of cancer vaccination pretreatment and activated “killer” T cell immunotherapy
Two-step Treatment. Explained.
Cancer treatment with ECI involves the following sequential and dependent steps:
Step One: Personalized vaccine stimulates a cancer-specific immune response.
- A. Cancer tissue is surgically removed by the veterinarian.
- B. This tissue is shipped to ELIAS Animal Health's manufacturing facility.
- C. A personalized vaccine is produced and sent back to the veterinarian.
- D. The vaccines are administered on a weekly or bi-weekly basis to stimulate the immune system T cells to recognize the dog's cancer.
Step Two: T Cell Harvest and Reinfusion.
- E. Two weeks following step one, the veterinary oncologist uses apheresis to harvest the population of cancer-specific
T cells generated by the vaccination.
- F. These T cells are shipped to ELIAS for processing.
- G. A proprietary, patented process is used to produce an activated, blood-derived population of T cells functionally
empowered and numerically expanded.
- H. This tumor-specific population of killer T cells is returned to the veterinarian for intravenous
Harvesting Process. Demystified.
Apheresis is a medical technology in which the whole blood of the patient can be passed through a medical instrument that separates out a particular component, in this case T cells, so they can be removed for further processing.
ECI Protocol. Timelined.
Although every patient and every experience is unique, there is a basic timeframe for ECI treatment and
evaluation. After the initial surgery to remove the cancer, a series of vaccinations will follow. After the
vaccinations, the personalized T cells are collected and activated. Following intravenous infusion of
activated ‘killer’ T cells, there may be several follow-up evaluations.
Therapeutic Potential. Amplified.
ECI is a promising oncology treatment modality for canine cancer for several reasons:
- It delivers the potential for
- Clinical outcomes of ELIAS' osteosarcoma trial, as reported at ACVIM in June, showed adverse events were mostly mild to moderate and were typically transient in nature.
- This personalized approach could be useful for treating numerous types of cancer and may limit or avoid the use of chemotherapy and radiation.
Preliminary Study Results & History of Treatment Outcomes